Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-11-23 | Augustine Lawlor, director, no software-related skills mentioned. |
| 2016-04-25 | Mr. Lawlor brings an important insight and knowledge to the Board based on his experience as a successful venture capitalist, service on the boards of public and private companies, and roles in commercial and business development in the pharmaceutical and biotechnology industries. |
| 2017-01-12 | Augustine Lawlor |
| 2017-05-18 | Mr. Lawlor has previously served as a director of Human Genome Sciences, which has since been acquired by GlaxoSmithKline and Replidyne, Inc. |
| 2018-05-11 | Mr. Lawlor brings an important insight and knowledge to the Board based on his experience as a successful venture capitalist, service on the boards of public and private companies, and roles in commercial and business development in the pharmaceutical and biotechnology industries. |
| 2019-05-02 | Mr. Lawlor has served as Chief Operating Officer of Leap Therapeutics, Inc., a Nasdaq-listed oncology company, and has been a Managing Director of HealthCare Ventures since 2000. He has held CFO and VP roles in biotech companies and was a management consultant with KPMG. He holds a Master’s in Public and Private Management from Yale University. |
| 2020-05-01 | Mr. Lawlor has served as Chief Operating Officer of Leap Therapeutics, Inc., a Managing Director of HealthCare Ventures, and held roles in corporate development and management consulting. He received his Master’s in Public and Private Management from Yale University. |
| 2021-04-27 | Mr. Lawlor received his Master’s in Public and Private Management from Yale University. |
Data sourced from SEC filings. Last updated: 2026-02-03